StageZero Life Sciences Ltd. announced that it has partnered with DiagnoseAtHome to make the Company's multi-cancer blood test, Aristotle®, available to DiagnoseAtHome's patients in Canada and the USA. Built on StageZero's proprietary mRNA gene expression technology platform, Aristotle is a next-generation test which simultaneously screens for multiple cancers from a single sample of blood. DiagnoseAtHome offers accessible at-home health and lab testing solutions, allowing businesses, organizations, and healthcare providers to offer safe, accurate and discreet lab testing to patients as an alternative to in-person laboratory visits.

Powered by a proprietary technology platform, DAH partners with telehealth organizations, assisted living, long-term care facilities, corporations, self-insured employers, healthcare providers, and clinics. Aristotle is the first-ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Aristotle test works by interrogating mRNA from a sample of whole blood and detecting gene expression profiles indicative of specific cancers.

Aristotle screens for the molecular signatures associated with multiple, individual cancers, including breast, ovarian, endometrial, colorectal, liver, stomach, prostate, and others.